➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Colorcon
AstraZeneca
Boehringer Ingelheim

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

Desipramine hydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for desipramine hydrochloride and what is the scope of patent protection?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Amneal Pharms Co, Ani Pharms Inc, Heritage Pharms Inc, Novast Labs, Sandoz, Usl Pharma, and Us Pharm Holdings, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for desipramine hydrochloride. Eight suppliers are listed for this compound.

Summary for desipramine hydrochloride
US Patents:0
Tradenames:3
Applicants:9
NDAs:22
Drug Master File Entries: 9
Suppliers / Packagers: 8
Bulk Api Vendors: 67
Clinical Trials: 60
Patent Applications: 1,981
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in desipramine hydrochloride?desipramine hydrochloride excipients list
DailyMed Link:desipramine hydrochloride at DailyMed
Recent Clinical Trials for desipramine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 4
Stanford UniversityPhase 4
State University of New York at BuffaloPhase 4

See all desipramine hydrochloride clinical trials

Pharmacology for desipramine hydrochloride
Medical Subject Heading (MeSH) Categories for desipramine hydrochloride

US Patents and Regulatory Information for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heritage Pharms Inc DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 207433-001 May 5, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal Pharms Co DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 208105-006 Mar 17, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 071803-003 Dec 8, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Mallinckrodt
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.